HALO FY 2023 Earnings Report — Halozyme Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

Halozyme Therapeutics, Inc.HALO

FY 2023 Earnings

Reported February 20, 2024

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2023	Prior Q	FY 2022	QoQ Change	YoY Change
Revenue	$829M	—	$660M	—	25.6%
Op. Income	$338M	—	$268M	—	26.2%
Gross Margin	76.8%	—	78.9%	—	-2.1pp
Net Margin	34.0%	—	30.6%	—	3.3pp
EPS (Diluted)	$2.10	—	$1.44	—	45.8%
Free Cash Flow	$373M	—	$235M	—	58.6%

Revenue Flow

Item	Amount
REVENUE	$829M
Cost of Revenue	$192M
GROSS PROFIT	$637M
R&D Expenses	$76M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$149M
Other Expenses	$74M
Operating Expenses	$299M
Cost & Expenses	$492M
OPERATING INCOME	$338M
Interest Income	$0
Interest Expense	$19M
Other Income/Expenses	$11M
INCOME BEFORE TAX	$348M
Income Tax Expense	$67M
Net Income from Continuing Ops	$282M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$282M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$282M
D&A	$85M
EBIT	$367M
EBITDA	$452M
EPS	$2
EPS Diluted	$2

Income Statement

Item	Amount
REVENUE	$829M
Cost of Revenue	$192M
GROSS PROFIT	$637M
R&D Expenses	$76M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$149M
Other Expenses	$74M
Operating Expenses	$299M
Cost & Expenses	$492M
OPERATING INCOME	$338M
Interest Income	$0
Interest Expense	$19M
Other Income/Expenses	$11M
INCOME BEFORE TAX	$348M
Income Tax Expense	$67M
Net Income from Continuing Ops	$282M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$282M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$282M
D&A	$85M
EBIT	$367M
EBITDA	$452M
EPS	$2
EPS Diluted	$2

Cash Flow Statement

Item	Amount
Net Income	$282M
Depreciation & Amortization	$85M
Stock-Based Compensation	$37M
Deferred Income Tax	$35M
Other Non-Cash Items	-$10M
Change in Working Capital	-$39M
OPERATING CASH FLOW	$389M
Capital Expenditure	-$15M
Acquisitions (Net)	$0
Purchases of Investments	-$293M
Sales/Maturities of Investments	$211M
Other Investing Activities	$0
NET CASH FROM INVESTING	-$97M
Net Debt Issuance	-$13M
Common Stock Repurchased	-$402M
Common Dividends Paid	$0
Other Financing Activities	$8M
NET CASH FROM FINANCING	-$408M
FREE CASH FLOW	$373M
Net Change in Cash	-$116M

Balance Sheet

Item	Amount
Cash & Equivalents	$118M
Short-Term Investments	$218M
Net Receivables	$234M
Inventory	$128M
Other Current Assets	$49M
TOTAL CURRENT ASSETS	$746M
PP&E (Net)	$75M
Goodwill	$417M
Intangible Assets	$473M
Long-Term Investments	$0
Tax Assets	$4M
Other Non-Current Assets	$18M
TOTAL NON-CURRENT ASSETS	$987M
TOTAL ASSETS	$1.7B
Account Payables	$12M
Short-Term Debt	$0
Deferred Revenue	$0
Other Current Liabilities	$0
TOTAL CURRENT LIABILITIES	$112M
Long-Term Debt	$1.5B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$38M
TOTAL NON-CURRENT LIABILITIES	$1.5B
TOTAL LIABILITIES	$1.6B
Common Stock	$127.0K
Additional Paid-In Capital	$2M
Retained Earnings	$91M
Treasury Stock	$0
Accum. Other Comp. Income	-$9M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$84M
Minority Interest	$0
TOTAL EQUITY	$84M
TOTAL LIABILITIES & EQUITY	$1.7B
Total Debt	$1.5B
Net Debt	$1.4B